Sun Pharma is recalling four lots of the muscle relaxant vecuronium bromide after glass fragments were found.

Pfizer's plan to close two legacy Hospira plants in India puts 1,700 jobs stationed there at risk.

Catalent plans $200 million investment to expand its drug manufacturing and drug product fill/finish at two plants.

Aurobindo issued a voluntary recall of 80 lots of valsartan tablets due to the detection of trace amounts of an impurity.

After more than a two-year delay, Portola will see the commercial release of Andexxa, a bleeding antidote for anticoagulants Xarelto and Eliquis.

French inspectors found a lot they didn’t like about an Indian manufacturer, leading the EMA to cite the facility.

The FDA and the pharma industry were surprised to learn a manufacturing process for "sartan" drugs might turn them into cancer-causing time bombs.

The cost of making upgrades to a money-losing plant may be the breaking point for Recipharm, which is weighing its closure.